中文名称 | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(烯丙基氨基)-13-羟基-8,14-二甲氧基-4,10,12,16-四甲基-3,20,22-三氧代-2-氮杂双环[16.3.1]二十二烷-1(21),4,6,10,18-戊烯-9-基 氨基甲酸酯;坦螺旋霉素 |
---|---|
英文名称 | Tanespimycin (Synonyms: 17-AAG; NSC 330507; CP 127374;KOS-953; KOS 953) |
CAS号 | 75747-14-7 |
分子式 | C31H43N3O8 |
分子量 | 585.69 |
MDL | MFCD04973892 |
外观 | Purple to purplish red powder |
储存条件 | 4°C, protect from ligh |
Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy.
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft